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ECM degradation by cultured human mesangial cells is mediated by a
PAjplasmin/MMP-2 cascade. We examined the role of the plasminogen
activator/plasmin system in extracellular matrix (ECM2 degradation by
human mesangial cells cultured on thin films of 1 51-Iabeled ECM
(Matrigel). ECM degradation (release of 25j into the medium) was
dependent on exogenous plasminogen, proportional to the number of
mesangial cells and amount of plasminogen added, and coincident with
the appearance of plasmin in the medium. ECM degradation was com-
pletely blocked (P < 0.001) by two plasmin inhibitors, a-2-antiplasmin (40
rgIml) and aprotinin (216 KIU/ml), and partially reduced (—33 1.8%,
P < 0.01) by TIMP-1 (40 .rWml), a specific inhibitor of matrix metallo-
proteinases. Zymography of medium obtained from cells cultured in the
absence of plasminogen revealed the presence of latent matrix metallo-
proteinase-2 (MMP-2) which was converted to a lower molecular weight,
active form in the presence of mesangial cells and plasminogen. Northern
analysis of poly A+ RNA prepared from cultured human mesangial cells
revealed mRNA for tissue-type plasminogen activator (tPA), urokinase-
type plasminogen activator (uPA), plasminogen activator inhibitor-i(PAl-i), and uPA receptor (uPAR). The presence of uPA protein in
medium obtained from cultured human mesangial cells was demonstrated
by Western blotting and ELISA which revealed a large molar excess of
PAl-I (1.2 0.1 x i0 M) over uPA (1.2 0.1 x 1012 M) and tPA (0.19
0.04 x iO M). ECM degradation was reduced by a monoclonal
antibody (MAb) against human tPA (—54 8.6%) or human uPA (—39
5.2%) compared to cells treated with identical amounts of non-specific
monoclonal IgG (P < 0.01). In contrast, MAb against human PAl-i
increased ECM degradation four-fold (P < 0.001). A MAb against human
uPAR had no significant effect on ECM degradation. Taken together, our
results indicate that ECM degradation by cultured human mesangial cells
is mediated by a proteinase cascade. This cascade is initiated by tPA and
generates plasmin and active MMP-2, which together carry out the
degradation of the ECM. We postulate that decreased activity of this
cascade may represent a final common pathway contributing to glomerular
ECM accumulation in progressive renal disease.
Accumulation of the glomerular mesangial matrix is a pivotal
event in the pathophysiology of progressive renal disease [1]. The
pathogenic mechanisms responsible for this accumulation are
unknown. However, decreased proteolysis is potentially an impor-
tant mechanism contributing to the accumulation of extracellular
matrix. Although several putative ECM degrading proteinases are
present in glomeruli and/or cultured mesangial cells [2—101, very
little information is available concerning the actual proteinases
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utilized by mesangial cells for degradation of the mesangial
matrix, the factors which regulate the activity of these proteinases,
or the potential role of these proteinases in glomerular disease.
In order to study ECM degradation under well-defined condi-
tions, we have developed an in vitro system utilizing mesangial
cells cultured on Matrigel, a readily available ECM which contains
the major components of the mesangial matrix, including laminin,
type IV collagen, entactin, and heparan sulfate proteoglycan.
Utilizing this system, we have documented that ECM degradation
by cultured rat mesangial cells is mediated by plasmin [10], a
serine proteinase with a broad substrate specificity including
several components of the ECM [11—13].
Plasmin is produced from plasminogen by two well-character-
ized plasminogen activators (PAs): urokinase-type PA (uPA) and
tissue-type PA (tPA) [12—141. Although mesangial cells synthesize
tPA [15, 16] and possibly uPA [17—20], the role of mesangial cell
PAs in ECM degradation has not been investigated. In the present
paper we have examined the role of tPA, uPA, and PAl-i, the
major naturally occurring PA inhibitor [21], in ECM degradation
by cultured human mesangial cells.
Methods
Reagents
Pepstatin A (catalog # P-4265), gelatin (from bovine skin, catalog
# G-1393), aprotinin (10,800 MU/mg protein, catalog # A-6297),
cs-2-antiplasmin (catalog # A-0914), and E-64 (trans-epoxysuccinyl-
L-leucyl-amido-(4-guanidino)butane) were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). RPM! 1640 cell culture
medium, 0.05% trypsin-0.5 mrvi EDTA, and Waymouth's medium
752/i were obtained from Gibco Labs (Grand Island, NY, USA).
Methoxysuccinyl-L-Ala-L-Phe-L-Lys-7-amido-4-methylcoumarin
(catalog # GME 080) was obtained from Bachem, Inc (Torrance,
CA, USA). Matrigel was obtained from Collaborative Research, Inc.
(Bedford, MA, USA) Na125! (451 mCi/mi), was obtained from New
England Nuclear (Bedford, MA, USA). Recombinant tissue inhibi-
tor of metalloproteinases-1 (TIMP-1) was a gift from Synergen Corp.
(Boulder, CO, USA).
The following murine monoclonal antibodies (MAb) were
obtained from American Diagnostica. MAb against human uPA
(# 394): recognizes all forms of uPA and uPA complexes; does
not recognize tPA. MAb against human tPA (# 374B): recognizes
sc-tPA, tc-tPA, tPA-PAI-1 complexes; does not react with uPA.
MAb against human PAl-I (# 379): recognizes free PAl-i as well
as tPA-PAI-1 and uPA-PAI-1 complexes, but does not recognize
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PAI-2. MAb against uPAR (# 3936): recognizes surface bound as
well as free uPAR; blocks 70% of the binding of FITC-uPA to
PMA-stimulated U937 cells. Plasminogen (# 410A), purified
high molecular weight uPA (# 125), two-chain tPA (# 116), and
methoxysulfonyl-cyclohexyl-Tyr-Gly-Arg-p-nitroanilide (# 444)
were obtained from American Diagnostica. The following ELISA
kits were also obtained from American Diagnostica: for uPA, kit
# 894 (sensitivity 10 pg/mI); for total tPA, kit # 160 (sensitivity
= 100 pg/mI); for free tPA, kit # 161 (sensitivity =500 pg/mI); for
PAl-i, kit # 822/iS (sensitivity < 0.5 ng/ml).
Pefabloc (4-(2-aminoethyl)-benzenesulfonyllluoride-HC1, # 1429868)
was obtained from Boehringer Mannheim (Indianapolis, IN,
USA). Glutaryl-Gly-Arg-AMC # 3097-v) was obtained from the
Peptide International (Louisville, KY, USA). All other chemicals
were reagent grade or higher and obtained from commercial
sources.
Mesangial cell culture
Human mesangial cells, obtained from Dr. Hanna Abboud (San
Antonio, TX, USA) were cultured in Waymouth's medium con-
taining 15% FCS, as described by Abboud and coworkers [22].
These cells have been extensively characterized as follows. All
cells were stellate or spindle shaped with irregular cytoplasmic
projections. The cells did not exhibit contact inhibition and
became multilayered if allowed to grow beyond confluency.
Immunoperoxidase staining was positive for desmin, myosin,
vimentin, and fibronectin and actin, and negative for the keratin,
von Willebrand factor, common leukocyte antigen, and DR
antigen. The cells do not express detectable amounts of angioten-
sin-converting enzyme activity. The mesangial cells used in these
studies were between the 9th and 15th passages.
Radiolabelling of Marrigel
'251-labeled Matrigel was produced by the chloramine-T
method as described by McConahey and Dixon [23], utilizing
sterile conditions as described in our previous paper [10]. Five
hundred (500) jsCi of Na'25! (451 mCi!ml) were added to 5.0 mg
of rapidly stirring Matrigel in 5.0 ml of phosphate-buffered saline
(PBS), pH 7.4, at 0 to 4°C followed by dropwise addition of 50 sg
of chloramine-T dissolved in 100 sl of PBS, pH 7.0. After 10
minutes, unreacted chloramine-T was neutralized by the addition
of 50 tg of sodium metasulfite in 100 d of PBS. Labeled Matrigel
was separated from unreacted 1251 by extensive dialysis at 0 to 4°C
against at least three changes of 500 ml of sterile PBS followed by
dialysis for 4 hours against 500 ml of sterile distilled water. The
'251-labeled Matrigel (specific radioactivity of 2 — 5 x 106 cpm/mg
protein) was stored at 0 to 4°C until used.
Measurement of ECM degradation by cultured human mesangial
cells
Thin films of radiolabeled Matrigel were produced in 24-well
culture plates as described previously [10]. Wells containing dried
Matrigel films (25 ig of protein, 20 to 25,000 cpm) were washed
three times with 1.0 ml of serum-free RPMI 1640 medium
immediately before addition of mesangial cells (25,000 cells per
well) in Waymouth's medium containing 15% fetal calf serum.
Plates were then incubated for 48 hours (37°C, 5.0% C02) to
allow the mesangial cells to attach to the Matrigel films and to
was carefully removed and the cells were washed three times with
1.0 ml of serum-free RPMI 1640 medium (to remove proteolytic
enzyme inhibitors potentially present in the serum) and then
incubated as above (usually for 72 hrs) in 500 d of serum-free
RPM! 1640 (without phenol red) containing 0.2% lactalbumin
hydrolyzate (RPMI-LH) as previously described by Lovett and
coworkers [7—9] for the short-term culture of mesangial cells in
serum-free medium. Exogenously added agents (such as plasmin-
ogen, proteinase inhibitors, monoclonal antibodies) were dis-
solved in RPMI-LH at the concentrations indicated in the tables
and figures.
ECM degradation by cultured mesangial cells was measured by
the release of radioactivity into the cell-free culture medium. At
the end of the incubation period (usually 72 hrs) the medium from
each well (500 j.Ll) was carefully removed, counted (gamma
counter) and stored at 0 to 4°C until other biochemical parame-
ters were measured (enzyme activity assays, substrate gels,
ELISA, etc.) as indicated below. ECM degradation is expressed as
mean SEM sg Matrigel degraded for the number of determina-
tions (each carried out in triplicate) indicated in each figure or
table. Matrigel degradation was calculated from the decay cor-
rected specific radioactivity of the Matrigel after correction for the
appropriate controls (Matrigel incubated with cells only; Matrigel
incubated with medium only; and Matrigel incubated with plas-
minogen only) included on each 24-well plate.
Enzyme activity measurements
Plasmin activity. Plasmin activity in medium obtained from
mesangial cells cultured on Matrigel films, appropriate controls,
and piasmin standards was determined using the synthetic fluoro-
metric plasmin substrate methoxysuccinyi-L-Ala-L-Phe-L-Lys-7-
amido-4-methyl-coumarin [24]. Up to 100 jtl of sample (cell-free
medium or plasmin standards) were mixed with 125 d of water
and 450 pA of 0.2 M Tris-HC1 pH 7.4, containing 0.2 M NaCI. Each
reaction was started at 15 second intervals by the addition of 225
pJ of methoxysuccinyl-L-Ala-L-Phe-L-Lys-7-AMC in water (final
substrate concentration, 5.0 tiM). Immediately after the addition
of substrate, each tube was mixed well, transferred to a 37°C water
bath, and capped to avoid evaporation during the incubation
period. After 40 minutes, each reaction was stopped at 15 second
intervals by the addition of 100 p1 of soya bean trypsin inhibitor
(0.25 mg/mi) followed by vigorous mixing. The fluorescence of
each tube was then measured in a Sequoia-Turner fluorometer
(Model 450) equipped with appropriate filters for AMC fluores-
cence (excitation at 360 nm; emission at 450 nm). Before each
series of readings, the fluorometer was set to zero with water and
to 1000 relative fluorescence units with 0.5 jtM AMC standard.
Tubes containing plasmin standards (0.25 and 0.50 mU) were
included in each set of assays as positive controls. Results are
expressed as the mean SEM nmoles AMC produced/well per 40
minutes incubation corrected for a duplicate blank (medium
added after stopper) carried out for each sample.
Plasminogen activator activity. Total plasminogen activator (PA)
activity (uPA plus tPA) in medium obtained from cultured
mesangial cells was determined by a modification of the plasmin
assay described above [24] based on the conversion of plasmino-
gen to plasmin in the presence of the plasmin substrate, methoxy-
succinyl-L-AIa-L-Phe-L-Lys-7-AMC. This method is similar to
that described above for plasmin except that plasminogen (final
recover from the plating procedures. After 48 hours, the medium concentration 0.3 sM) is included in the incubation cocktail. After
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an incubation of 60 minutes, the reaction was stopped by the
addition of 4-(2-aminoethyl)-benzenesulfonylfluoride-HCI (Pefa-
bloc, final concentration 1.0 mM) and AMC production measured
as described above for plasmin. A positive control, consisting of 30
lU/tube of uPA, was run simultaneously with each assay. Each
sample was assayed in duplicate and results corrected for a sample
blank which consisted of medium added after the stopper.
uPA activity. uPA activity in medium obtained from cultured
human mesangial cells was examined using synthetic fluorogenic
substrate Glutaryl-Gly-Arg-AMC as described by Morita et a!
[25]. Up to 400 .d of medium or 20 IU of standard uPA
(American Diagnostica # 125, 160,000 lU/mg) were incubated at
37°C for 1 hour with the substrate (final concentration, 5.0 M) in
0.2 M Tris-HC1 pH 7.5, containing 0.2 M NaC1, 20 mivi EDTA, and
20 KIU aprotinin in a final volume of 1.80 ml. The reaction was
stopped by the addition of 200 jd Pefabloc (final concentration,
1.0 mM) and the amount of AMC generated was measured as
above. Each sample was measured in duplicate and uPA activity
was determined by comparison with the uPA standard run
simultaneously with each assay following correction for a sample
blank consisting of medium added after the stopper.
tPA activity. tPA activity in medium obtained from cultured
human mesangial cells, appropriate controls, and standards was
determined using the substrate methoxysulfonyl-cyclo-hexyl-Tyr-
Gly-Arg-p-nitroanilide (pNA) (Spectrozyme tPA, American Di-
agnostica # 444) as described by American Diagnostica. Up to
400 d of medium or 40 IU tPA standard (positive control,
American Diagnostica #116, 731,000 lU/mg) were incubated at
37°C for 1 hour with substrate (final concentration 16 nM) in
Tris-imidazole buffer, pH 8.4, containing 20 KIU aprotinin, and 20
mM EDTA in a final volume of 1.8 ml. After 1 hour, the reaction
was stopped by the addition of 200 jti of Pefabloc (final concen-
tration 1.0 mM) and tPA activity determined by spectrophotomet-
nc measurement of the released pNA at 405 nm. Each sample was
measured in duplicate and tPA activity was determined by com-
parison with the standard run simultaneously with each assay
following correction for a sample blank consisting of medium
added after the stopper.
Zymography
Gelatin substrate SDS-PAGE was carried out by incorporating
gelatin (Sigma, # GI 393, 500 pg/ml) into standard 10% polyacryl-
amide gels [26] as described in our previous paper [10]. Because
SDS activates latent matrix metalloproteinases, this technique
allows the detection and characterization of both latent and active
forms of these proteinases.
Quantitation of uPA, tPA, and PAl-i protein by enzyme linked
immunosorbent assay (ELISA)
Quantitative measurement of uPA, tPA, and PAl-i were car-
ried out according to the manufacturer's instructions utilizing the
ELISA kits listed above. The following volumes of undiluted
medium were used: for uPA, 100 1; for tPA 60 tl; for PAl-i, 6
jil. Each sample was measured in duplicate and the amount of
uPA, tPA and PAT-i determined from a standard curve (run
simultaneously with the samples) after correction for the appro-
priate control (medium obtained from wells containing plasmin-
ogen only).
Northern analysis
Confluent human mesangial cells, grown in 75 cm2 culture
flasks, were placed in serum-free RPMI-1640 for 24 hours prior to
RNA isolation. Cells were washed twice with phosphate-buffered
saline, pH 7.4 (without Ca2 or Mg2), and total RNA extracted
by the acid guanidinium thiocyanate-chioroform-phenol extrac-
tion method of Chomczynski and Sacchi [27]. Total RNA from
seven confluent flasks was pooled and poly A+ RNA prepared by
chromatography on oligo-dT cellulose (Gibco, # 15939-010) as
described by the manufacturer. For Northern blotting, 5 tg of
poly A+ RNA were subjected to denaturing electrophoresis (1%
agarose formaldehyde gel) and vacuum-transferred to a nylon
membrane (Genescreen Plus). The membrane was cross-linked
via UV exposure and prehybridized for 1 hour at 65°C in 0.1 X
SSPE, 1.0% SDS. A 1.1 kb eDNA for uPAR [28] and a 1.9 kb
eDNA for PAl-i [29] were obtained from Dr. Elliot Barnathan
(University of Pennsylvania School of Medicine). The cDNAs for
tPA (2.2 kb, 30) and uPA (1.3 kb, 31) were obtained from Dr. D.
Dichek, National Heart Lung and Blood Institute. The intact
plasmids were labeled with 32P-dCTP by the random primer
method as described by the manufacturer (Random Primer DNA
labeling Kit, Gibco BRL 18187-013). Prehybridized membranes
were hybridized for 18 to 24 hours at 65°C in 250 m sodium
phosphate buffer, pH 7.2, containing 7% SDS, 1 mM EDTA, 10
mg/mi BSA, and 0.1 mg/mi salmon sperm DNA. The membrane
was washed two times at 65°C in 20 m sodium phosphate buffer,
pH 7.2, containing 1% SDS, 1 mivi EDTA, and 2 mg/mI BSA,
followed by four washes in 20 m sodium phosphate buffer, pH
7.2, containing 1% SDS and 1 mM EDTA. Autoradiography was
performed by standard procedures using preflashed Kodak X-
OMAT XAR film.
Western blotting
Western blotting of medium obtained from cultured human
mesangial cells was carried out by standard techniques. Fifteen d
of 100-fold concentrated (Amicon Centriprep-lO) serum-free
medium were mixed with 5 1.d of gel sample buffer and subjected
to SDS-PAGE in a 10% polyaciylamide gel essentially as de-
scribed by Laemmli [26]. Separated proteins were transferred to a
nitrocellulose membrane using a BioRad semidry transfer cell (30
mm at 15 volts). Unoccupied sites on the membrane were blocked
by treatment with 0.5% casein for 1 hour at 37°C. After thorough
washing with Tris-buffered saline, pH 7.6 (buffer), the membrane
was incubated overnight at room temperature with buffer contain-
ing 5 jLg/ml anti-human uPA antibodies (American Diagnostica,
# 394). The membrane was washed five times with buffer and then
incubated for 1 hour at room temperature with 2 g/ml HRP
conjugated anti-mouse IgG (Chemicon, AP181P) in buffer fol-
lowed by five washes, 5 minutes each, with the same buffer. The
washed membrane was then incubated with 4-chloro-i-napthol
and hydrogen peroxide until purple bands appeared (approxi-
mately 5 to 10 mm).
Results
Role of plasmin
We first examined the ability of cultured human mesangial cells
to degrade ECM. As shown in Figure 1A, ECM degradation
occurred only in the presence of exogenous plasminogen and was
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Fig. IA. Plasminogen dependence of ECM degradation by cultured human
mesangial cells. Cultured human mesangial cells (25,000/well) were plated
on thin films of '251-labeled Matrigel (approximately 25,000 cpm/well) in
Waymouth's medium containing 15% FCS. After 48 hours, cells were
washed 3 times with 1 ml of serum-free RPMI 1640 containing 0.2%
lactalbumin hydrolysate (Med) and cells cultured for an additional 72
hours in 500 jsl of RPMI-LH in the presence or absence of 2 jtg of
plasminogen (Pign) as indicated in the figure. Seventy-two hours after the
addition of plasminogen, radioactivity released into the cell-free medium
was determined as described in Methods. Symbols are: (El) ECM degra-
dation; () plasmin activity. Results are expressed as mean SEM of 3
determinations. If no SEM bar is shown, it is too small to be seen.
* indicates significantly different from other experimental conditions, P <
0.01. Further details are given in Methods. B. Effect of cell number on
ECM degradation by cultured human mesangial cells. Varying numbers of
cultured human mesangial cells were plated on thin films of '251-labeled
Matrigel and processed as described for A. After 48 hours, cells were
washed 3 times with 1 ml of serum-free RPMI 1640 containing 0.2%
lactalbumin hydrolysate (RPMI-LH) and cells cultured for an additional
72 hours in 500 pd of RPMI-LH in the presence of 2 jsg of plasminogen.
After 72 hours, radioactivity present in the cell-free medium was counted
and ECM degradation determined as described in Methods. Results are
expressed as mean SEM of 3 determinations. If no SCM bar is shown, it
is too small to be seen. Further details are given in Methods. C. Effect of
increasing amounts of plasminogen on ECM degradation by cultured
human mesangial cells. Cultured human mesangial cells (25,000/well)
were plated on thin films of '251-labeled Matrigel and processed as in A.
After 48 hours, cells were washed 3 times with 1 ml of serum-free RPMI
1640 containing 0.2% lactalbumin hydrolysate (RPMI-LH) and cells
cultured for an additional 72 hours in 500 jd of RPMI-LH in the presence
of the amount of plasminogen indicated below each bar. Results are
expressed as mean SCM of 3 determinations. If no SCM bar is shown, it
is too small to be seen. Further details are given in Methods.
Table 1. Effects of proteinase inhibitors on ECM degradation by
cultured human mesangial cells
Inhibitor
jg ECM
degraded % control
None 5.4 0.1 100
E-64, 10 pM 5.3 0.2 98
Pepstatin, 5.0 pg/mI 5.2 0.2 96
TIMP-1, 40 pg/mI 3.6 0.2 67*
02 -antiplasmin, 40 pg/mI 0 0b
Aprotinin, 216 KIU/ml 0 0b
'P < 0.01 vs. control (no inhibitor); "P < 0.001 vs. control (no
inhibitor).
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coincident with the appearance of plasmin in the medium. Addi-
tional studies demonstrated that ECM degradation was propor-
tional to the number of mesangial cells added to each well (Fig.
1B) and to the amount of plasminogen added (Fig. IC). These
results indicate an important role for plasmin in ECM degrada-
tion by cultured human mesangial cells.
In order to document further the role of plasmin and to
examine the potential role of other proteinases in ECM degrada-
tion by cultured human mesangial cells, we examined the effects of
selected proteinase inhibitors. As shown in Table 1, inhibitors of
cysteine proteinases (E-64, 10 LM) and aspartic proteinases
(pepstatin, 5.0 jig/mI) had no significant effect on ECM degrada-
tion. In contrast, two inhibitors of plasmin, a-2-antiplasmin (40
jig/mi) and aprotinin (216 KIU/ml), produced complete inhibition
of ECM degradation confirming the role of plasmin in ECM
degradation by cultured human mesangial cells.
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Fig. 2. Zymogram of cell-free medium obtained from cultured mesangial cells grown on thin films of Matrigel. Cultured human mesangial cells (25,000/well)
were plated on thin films of 251-labeled Matrigel and processed as in Figure IA. After 48 hours, cells were washed 3 times with 1 ml of serum-free RPMI
1640 containing 0.2% lactalbumin hydrolysate (RPMI-LH) and cells cultured for an additional 72 hours in 500 .d of RPM 1-LIT under the following
conditions: in the presence (lane 4) or absence (lane 5) of 2 g of plasminogen; in the presence of 2 g of piasminogen + 20 rg a-2-antiplasmin (lane
6); or in the presence of 2 jg of plasminogcn + aprotinin (108 KIU, lane 7). After 72 hours, 30 i.tl of cell-free medium were mixed with 10 l of gel
sample buffer and 15 il of this mixture used for gelatin substrate SDS-PAGE (zymography) as described in Methods. Molecular weight standards are
present in lanes 2 and 9. Lanes 1, 3, 8, and 10 are empty. Arrow indicates the position of albumin, molecular weight 66.2 kDa. Further details are given
in Methods,
Role of matrix metalloproteinase 2 (MMP-2)
In addition to plasmin inhibitors, tissue inhibitor of metallopro-
teinases (TIMP-1), a specific inhibitor of matrix metalloprotein-
ases (MMPs, 32), also reduced ECM degradation (—33 1.8%,
P < 0.01), suggesting that in addition to plasmin, a MMP was also
involved (Table 1). Gelatin substrate SDS-PAGE of medium
obtained from mesangial cells incubated in the absence of plas-
minogen revealed one major band of proteinase activity, molec-
ular weight approximately 66 kD (Fig. 2). This proteinase activity
comigrated with authentic MMP-2 (a gift of Dr. Gillian Murphy,
Cambridige, UK) and was completely inhibited by 10 mM EDTA
(not shown), indicating that it is a truncated form of MMP-2. The
lack of ECM degradation in the absence of plasminogen, despite
the presence of this proteinase in the medium, indicates that it is
latent MMP-2 (latent MMPs are activated by SDS, present in the
buffers used for the electrophoresis). In medium obtained from
cells incubated in the presence of plasminogen (which is con-
verted to plasmin by mesangial cell PAs), a second band of
proteinase activity (approximately 57 kD) was present (Fig. 2).
This band was absent (or very faint) in medium obtained from
cells incubated in the absence of plasminogen and in medium
from cells incubated in the presence of plasminogen and plasmin
inhibitors such as cs-2-antiplasmin or aprotinin (Fig. 2). In con-
trast, it was always present in medium obtained from cells which
degraded ECM (data not shown). These data indicate that this
lower molecular weight band is active MMP-2.
Production of uPA, tPA, PAl-I, and uPAR by cultured human
mesangial cells
In order to determine which components of the PA/plasmin
system are produced by cultured human mesangial cells, we
utilized Northern analysis to examine the presence of mRNA for
uPA, tPA, PAl-i, and uPAR. Northern analysis of polyA+ RNA
prepared from cultured mesangial cells revealed the presence of a
single transcript for tPA (2.7 kb) and uPAR (1.5 kb), and two
transcripts for PAl-i, 3.2kb and 2.3 kb (Fig. 3A) which are
thought to arise from variable polyadenylation [21]. As shown in
Figure 3A, we also observed mRNA for uPA (2.5 kb). Because
uPA production by cultured human mesangial cells is controver-
sial (15, 16, 18 to 20, 33) we also examined uPA production by
Western blotting and ELISA. In keeping with the results of our
Northern analysis, Western blotting of 100-fold concentrated
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Fig. 3. A. Northern analysis of polyA + RNA isolated from cultured human mesangial cells. Human mesangial cells were cultured in 75 cm2 tissue culture
flasks in Waymouth's medium containing 15% FCS as described in Methods. At confluency, cells were washed 3 times with DEPC-treated phosphate
buffered saline and poly A+ RNA was prepared as described in Methods. Because the figure shown represents a composite made up of blots prepared
at different times, relative positions of mRNA bands may not align exactly according to their size. Sizes of mRNA bands are: tPA, 2.7 kb; uPAR, 1.5
kb; PAl-I, 3.2 and 2.3 kb; uPA, 2.5 kb. Details concerning the eDNA probes and hybridization conditions are given in Methods. Abbreviations are: tPA,
tissue plasminogen activator; uPAR, uPA receptor; uPA, urokinase-type plasminogen activator; PAl-i, plasminogen activator inhibitor 1. B. Western
blot demonstrating immunoreactive uPA protein in medium obtained from cultured human mesangial cells. Cultured human mesangial cells
(25,000/well) were plated on thin films of '25I-labeled Matrigel (approximately 25,000 cpm/well) in Waymouth's medium containing 15% FCS. After 48
hours, cells were washed 3 times with 1 ml of serum-free RPMI 1640 containing 0.2% lactalbumin hydrolysate (RPMI-LH) and cells cultured for an
additional 72 hours in 500 jd of RPMI-LH in the absence of plasminogen. Medium from several wells was pooled, concentrated (approximately
100-fold), and used for Western blotting as described in Methods. Abbreviation is: uPA, urokinase-type plasminogen activator. The position of the band
shown is approximately 55 kD.
medium demonstrated the presence of a band of uPA protein
(Fig. 3B). ELISA of uPA, tPA and PAl-i revealed a large molar
excess of PAl-i protein (1.2 0.1 X i0 M, N = 19) over uPA
(1.2 0.1 X 10— 12 M, N = 10) and tPA (0.19 0.04 X i0 M,N = ii). As expected, based on the molar excess of PAl-i over
tPA and uPA, no PA enzymatic activity could be detected in
medium obtained from cultured human mesangial cells using
either synthetic substrates or the conversion of plasminogen to
plasmin. In addition, no free tPA could be detected using an
ELISA specific for free tPA (American Diagnostica, kit # 161).
These results are in agreement with those of Glass et al [18] and
Lacave et al [15] who observed a large molar excess of PAl-i over
PAs and lack of PA enzyme activity in medium [15] and adhesion
placques [18] obtained from cultured human mesangial cells.
Role of uPA, tPA, uPAR, and PAl-i in ECM degradation
To investigate the role of the uPA, tPA, PAl-i, and uPAR in
ECM degradation by cultured human mesangial cells, we exam-
ined the effects of monoclonal antibodies raised against each of
these components of the PA/plasmin system (see Methods for
specific information about each monoclonal antibody). A mono-
clonal antibody against uPAR had no significant effect on ECM
degradation suggesting that uPAR does not play a major role in
ECM degradation by cultured human mesangial cells (discussed
further below). However, monoclonal antibodies against either
uPA or tPA significantly reduced ECM degradation compared to
either cells treated with an identical amount of non-immune
monoclonal IgG or controls which contained no IgG (Fig. 4A). In
contrast, a monoclonal antibody against PAl-i increased ECM
degradation four-fold (Fig. 4B). These data provide further
evidence for the production of uPA and indicate important roles
for uPA, tPA, and PAl-i in ECM degradation by cultured human
mesangial cells.
Discussion
Previously published studies based on immunofluorescence,
Western blotting, and zymography indicate that human mesangial
cells produce tPA, PAl-i, and uPAR [15, 16, 18] and Glass et at
[17] have reported that cultured rat mesangial cells produce uPA.
However, the synthesis of uPA by human mesangial cells is
controversial, with both positive [18—201 and negative [15, 16, 33]
results being reported. Our data, based on three separate meth-
odologies (Northern analysis, Western blotting, and ELISA)
establish that cultured human mesangial cells produce uPA in
addition to tPA, PAl-I and uPAR. The ability of antibodies
against uPA to reduce ECM degradation (Fig. 4A) provides
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Fig. 4A and B. Effects of monoclonal antibodies against specific compo-
nents of the PA/plasmin system on ECM degradation by cultured human
mesangial cells. Cultured human mesangial cells (25,000/well) were plated
on thin films of 1251-labeled Matrigel (approximately 25,000 cpm/well) in
Waymouth's medium containing 15% FCS. After 48 hours, cells were
washed 3 times with 1 ml of serum-free RPMI 1640 containing 0.2%
lactalbumin hydrolysate (RPMI-LH) and cells cultured for an additional
72 hours in 500 td of RPMI-LH in the presence 2 jg of plasminogen and
4 tg of the monoclonal antibody to be tested or 4 g of non-immune
monoclonal IgG as indicated below each bar. Abbreviations are: Anti-
uPA, monoclonal antibody against urokinase-type plasminogen activator;
Anti-tPA, monoclonal antibody against tissue-plasminogen activator; An-
ti-uPAR, monoclonal antibody against urokinase-type plasminogen acti-
vator receptor; Anti-PAT-I, monoclonal antibody against plasminogen
activator inhibitor 1. After 72 hours, radioactivity released into the
cell-free medium was determined as described in Methods. Results are
expressed as mean percent control SCM for the number of determina-
tions (carried out in triplicate) shown in each bar. * indicates significantly
different from control (no additions), P < 0.01. ** indicates significantly
different from wells containing 4 jg of non-immune IgG, P < 0.01. The
IgG controls shown in 4A and 4B are the same samples. Further details
are given in Methods.
further support for uPA production by cultured human mesangial
cells. It may be worth noting that we could not detect mRNA for
uPA in Northern analysis using 20 j.g of total RNA. We suggest
that the failure of other workers to observe uPA production by
cultured human mesangial cells may be due to the relatively low
amount of uPA produced combined with the relative insensitivity
of the methods used (such as immunohistochemical localization
and in situ hybridization) and differences in the sensitivity of
antibodies used for ELISA.
Although mesangial cells are known to produce MMP-2 (72 kD
type IV collagenase), its role in ECM degradation has been
speculative [7—10]. Our data (Table 1 and Fig. 2) indicate that in
addition to plasmin, MMP-2 also participates in ECM degrada-
tion by cultured human mesangial cells. Similar to other matrix
metalloproteinases, MMP-2 is synthesized as an inactive zymogen
which must be activated by limited proteolysis of the amino
terminus in order to become proteolytically active [32, 34].
Although a variety of functionally unrelated agents can activate
MMP-2 in vitro [32, 34], the physiological activator is unknown.
The ability of plasmin (and other proteolytic enzymes) to activate
latent MMP-1 (interstitial collagenase) and latent MMP-3
(stromelysin) is well-documented [13] and suggests that plasmin
may activate latent MMP-2 in our system. Indeed, activation of
latent MMP-2 by plasmin has been reported [35, 36] although
others have failed to confirm these results [37, 38]. One possible
explanation for these differences is that the activation of latent
MMP-2 by plasmin may be indirect, for example by inactivation of
TIMPs, or by activation of a second proteinase which then
activates latent MMP-2. Nagase and coworkers [391 have reported
that plasmin does not inactivate TIMP-1. However, Keski-Oja et
al [35] reported activation of latent MMP-2 in vitro by uPA (but
not tPA), a finding that we have confirmed in preliminary studies
(Baricos and Cortez, unpublished observation). Thus, we suggest
that the major function of uPA in this system may be activation of
latent MMP-2. Such a function is consistent with the surprising
reduction in ECM degradation produced by anti-uPA antibodies
(given the low concentration of uPA relative to tPA) and the
similar reductions in ECM degradation produced by anti-uPA
antibodies and TIMP-1.
It is important to point out that although Matrigel may contain
trace amounts of MMP-2, MMP-9 [40], and plasminogen activa-
tors [41], these proteinases, if present, do not contribute signifi-
cantly to ECM degradation in our system as indicated by the fact
that significant ECM degradation occurs only in the presence of
mesangial cells and plasminogen (Fig. 1).
Taken together, our data indicate that ECM degradation by
cultured human mesangial cells involves a PA/plasmin/MMP-2
proteinase cascade (Fig. 5). This cascade is initiated by either uPA
or tPA and results in the production of plasmin and active MMP-2
which then directly degrade the ECM. However, the failure of
antibodies against uPAR to significantly decrease ECM degrada-
tion suggests that the uPA-uPAR complex [42—44] does not play
a major role in ECM degradation in our system. Thus, our data
indicate that this cascade is initiated by single chain tPA (sc-tPA),
which is known to have significant enzymatic activity [45]. The
plasmin produced by sc-tPA could then convert sc-tPA and
sc-uPA to tc-tPA and tc-uPA, respectively [46, 47], which are
much more active than the single chain forms in the conversion of
plasminogen to plasmin. Plasmin can then degrade the non-
collagenous components of the ECM. As mentioned above,
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tc-uPAcould activate latent MMP-2, which can then degrade type
IV collagen.
Several independent lines of evidence suggest an important role
for the PAlplasmin system in glomerular ECM catabolism in vivo.
The presence of plasminogen activator and PAl-i in glomeruli of
both animals [48—51] and humans [52—55] is well-documented.
Decreased PA activity and/or increased levels of PAl-i have been
observed in glomeruli obtained from animals and humans with
glomerular diseases known to be associated with ECM accumu-
lation. For example, Feng et al [48] and Malliaros et al [51]
reported decreased PA levels and increased PAl-I levels in
glomeruli isolated from rats and rabbits with glomerular ECM
accumulation due to antiGBM antibody disease. Similar results
were reported by Border and coworkers [49] for glomeruli
isolated from rats with antithymocyte antibody-induced GN;
Loskutoff et al [50] who reported over-expression of PAl-i in
glomeruli from 33 out of 34 mice with lupus nephritis; and
Rondeau et al [54] who observed increased levels of PAl-i in
glomeruli from patients with vascular nephropathy and crescentic
GN.
These studies, combined with our data presented above, suggest
that the PA/plasmin/MMP-2 cascade is a major pathway of ECM
degradation in mesangial cells and intact glomeruli and raise the
possibility that decreased activity of the PA/plasmin/MMP-2
cascade may constitute a final common pathway of glomerular
ECM accumulation in progressive renal disease.
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